246 related articles for article (PubMed ID: 27431938)
1. The transporter and permeability interactions of asymmetric dimethylarginine (ADMA) and L-arginine with the human blood-brain barrier in vitro.
Watson CP; Pazarentzos E; Fidanboylu M; Padilla B; Brown R; Thomas SA
Brain Res; 2016 Oct; 1648(Pt A):232-242. PubMed ID: 27431938
[TBL] [Abstract][Full Text] [Related]
2. Interaction of the cardiovascular risk marker asymmetric dimethylarginine (ADMA) with the human cationic amino acid transporter 1 (CAT1).
Strobel J; Mieth M; Endress B; Auge D; König J; Fromm MF; Maas R
J Mol Cell Cardiol; 2012 Sep; 53(3):392-400. PubMed ID: 22705145
[TBL] [Abstract][Full Text] [Related]
3. Ammonia Reduces Intracellular Asymmetric Dimethylarginine in Cultured Astrocytes Stimulating Its y⁺LAT2 Carrier-Mediated Loss.
Milewski K; Bogacińska-Karaś M; Fręśko I; Hilgier W; Jaźwiec R; Albrecht J; Zielińska M
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29099056
[TBL] [Abstract][Full Text] [Related]
4. Cationic amino acid transport across the blood-brain barrier is mediated exclusively by system y+.
O'Kane RL; Viña JR; Simpson I; Zaragozá R; Mokashi A; Hawkins RA
Am J Physiol Endocrinol Metab; 2006 Aug; 291(2):E412-9. PubMed ID: 16569760
[TBL] [Abstract][Full Text] [Related]
5. Asymmetric dimethylarginine impairs glucose utilization via ROS/TLR4 pathway in adipocytes: an effect prevented by vitamin E.
Yang ZC; Wang KS; Wu Y; Zou XQ; Xiang YY; Chen XP; Li YJ
Cell Physiol Biochem; 2009; 24(1-2):115-24. PubMed ID: 19590199
[TBL] [Abstract][Full Text] [Related]
6. Nitric oxide synthase inhibition and oxidative stress in cardiovascular diseases: possible therapeutic targets?
Rochette L; Lorin J; Zeller M; Guilland JC; Lorgis L; Cottin Y; Vergely C
Pharmacol Ther; 2013 Dec; 140(3):239-57. PubMed ID: 23859953
[TBL] [Abstract][Full Text] [Related]
7. Effects of simvastatin on CAT-1-mediated arginine transport and NO level under high glucose conditions in conditionally immortalized rat inner blood-retinal barrier cell lines (TR-iBRB).
Tun T; Kang YS
Microvasc Res; 2017 May; 111():60-66. PubMed ID: 28089735
[TBL] [Abstract][Full Text] [Related]
8. Asymmetric dimethylarginine regulates the lipopolysaccharide-induced nitric oxide production in macrophages by suppressing the activation of NF-kappaB and iNOS expression.
Pekarova M; Kubala L; Martiskova H; Bino L; Twarogova M; Klinke A; Rudolph TK; Kuchtova Z; Kolarova H; Ambrozova G; Kuchta R; Kadlec J; Lojek A
Eur J Pharmacol; 2013 Aug; 713(1-3):68-77. PubMed ID: 23665490
[TBL] [Abstract][Full Text] [Related]
9. Plasma concentrations of arginine and asymmetric dimethylarginine do not reflect their intracellular concentrations in peripheral blood mononuclear cells.
Davids M; Teerlink T
Metabolism; 2013 Oct; 62(10):1455-61. PubMed ID: 23890667
[TBL] [Abstract][Full Text] [Related]
10. Age-related changes in ADMA-DDAH-NO pathway in rat liver subjected to partial ischemia followed by global reperfusion.
Trocha M; Merwid-Ląd A; Chlebda-Sieragowska E; Szuba A; Pieśniewska M; Fereniec-Gołębiewska L; Kwiatkowska J; Szeląg A; Sozański T
Exp Gerontol; 2014 Feb; 50():45-51. PubMed ID: 24269305
[TBL] [Abstract][Full Text] [Related]
11. Asymmetric dimethylarginine induces oxidative and nitrosative stress in murine lung epithelial cells.
Wells SM; Holian A
Am J Respir Cell Mol Biol; 2007 May; 36(5):520-8. PubMed ID: 17158357
[TBL] [Abstract][Full Text] [Related]
12. Developmental changes of l-arginine transport at the blood-brain barrier in rats.
Tachikawa M; Hirose S; Akanuma SI; Matsuyama R; Hosoya KI
Microvasc Res; 2018 May; 117():16-21. PubMed ID: 29247719
[TBL] [Abstract][Full Text] [Related]
13. Increased symmetrical dimethylarginine in ischemic acute kidney injury as a causative factor of renal L-arginine deficiency.
Betz B; Möller-Ehrlich K; Kress T; Kniepert J; Schwedhelm E; Böger RH; Wanner C; Sauvant C; Schneider R
Transl Res; 2013 Aug; 162(2):67-76. PubMed ID: 23707198
[TBL] [Abstract][Full Text] [Related]
14. Coordinated regulation of dimethylarginine dimethylaminohydrolase-1 and cationic amino acid transporter-1 by farnesoid X receptor in mouse liver and kidney and its implication in the control of blood levels of asymmetric dimethylarginine.
Li J; Wilson A; Gao X; Kuruba R; Liu Y; Poloyac S; Pitt B; Xie W; Li S
J Pharmacol Exp Ther; 2009 Oct; 331(1):234-43. PubMed ID: 19605523
[TBL] [Abstract][Full Text] [Related]
15. The role of asymmetric dimethylarginine and arginine in the failing heart and its vasculature.
Visser M; Paulus WJ; Vermeulen MA; Richir MC; Davids M; Wisselink W; de Mol BA; van Leeuwen PA
Eur J Heart Fail; 2010 Dec; 12(12):1274-81. PubMed ID: 20923854
[TBL] [Abstract][Full Text] [Related]
16. Adverse effects of cigarette smoke on NO bioavailability: role of arginine metabolism and oxidative stress.
Zhang WZ; Venardos K; Chin-Dusting J; Kaye DM
Hypertension; 2006 Aug; 48(2):278-85. PubMed ID: 16801489
[TBL] [Abstract][Full Text] [Related]
17. Lysophosphatidylcholine-induced elevation of asymmetric dimethylarginine level by the NADPH oxidase pathway in endothelial cells.
Jia SJ; Jiang DJ; Hu CP; Zhang XH; Deng HW; Li YJ
Vascul Pharmacol; 2006 Mar; 44(3):143-8. PubMed ID: 16309971
[TBL] [Abstract][Full Text] [Related]
18. Transport of asymmetric dimethylarginine (ADMA) by cationic amino acid transporter 2 (CAT2), organic cation transporter 2 (OCT2) and multidrug and toxin extrusion protein 1 (MATE1).
Strobel J; Müller F; Zolk O; Endreß B; König J; Fromm MF; Maas R
Amino Acids; 2013 Oct; 45(4):989-1002. PubMed ID: 23864433
[TBL] [Abstract][Full Text] [Related]
19. Asymmetric dimethylarginine (ADMA) and other endogenous nitric oxide synthase (NOS) inhibitors as an important cause of vascular insulin resistance.
Toutouzas K; Riga M; Stefanadi E; Stefanadis C
Horm Metab Res; 2008 Sep; 40(9):655-9. PubMed ID: 18792879
[TBL] [Abstract][Full Text] [Related]
20. Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA).
Maas R
Vasc Med; 2005 Jul; 10 Suppl 1():S49-57. PubMed ID: 16444869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]